January 31, 2026

Case Study: ICU-Based Chemotherapy for High-Risk Cardiac DLBCL Patient

A 34-year-old woman with newly diagnosed mediastinal diffuse large B-cell lymphoma developed alarming cardiac symptoms during her initial hospitalization.

Temple Health

January 29, 2026

Can a BiTE Immunotherapy Improve Survival in Young Patients with High-Risk Kinase-Driven B-ALL Subtypes?

Two genetic subtypes of childhood B-cell acute lymphoblastic leukemia (B-ALL) have long been associated with inferior treatment outcomes: Philadelphia chromosome-positive (Ph+) and ABL-class Philadelphia chromosome-like (Ph-like) B-ALL.

Roswell Park Comprehensive Cancer Center

January 28, 2026

Nivolumab Added to Chemoradiotherapy Reduced Recurrence Risk in High-Risk Head and Neck Cancer

Adding the PD-1 inhibitor nivolumab to standard chemoradiotherapy after surgery significantly reduced recurrence rates for patients with locally advanced head and neck squamous cell carcinoma who are ...

The ASCO Post

January 28, 2026

Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standar...

The ASCO Post

January 28, 2026

AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging

“The new staging will better inform clinicians and patients about a patient’s prognosis and will minimize inconsistencies in the treatments patients are offered.”

The ASCO Post

January 27, 2026

Bacterial Decolonization to Manage Acute Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma

Based on the results of a single-center phase III Chinese trial, which were published by Liao et al in JAMA Oncology, bacterial decolonization therapy with the antibiotic mupirocin may be an effective...

The ASCO Post

January 27, 2026

Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck

In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemor...

The ASCO Post

January 27, 2026

10-Year Incidence of Second Cancers in HPV-Positive Oropharyngeal Cancer

At 10 years, the cumulative incidence of radiation-induced second malignancies in patients receiving definitive radiation therapy for oropharyngeal cancers associated with human papillomavirus (HPV) w...

The ASCO Post

January 27, 2026

Oropharyngeal Cancer in the United States: Recent Estimates and Future Trends

A cross-sectional epidemiologic analysis found that the incidence of oropharyngeal cancer has increased among older individuals, and those with localized disease appeared to be undertreated.

The ASCO Post